Hypoactive Sexual Desire Disorder (HSDD) Guidelines Compared: What Every Woman Should Know

What Is HSDD and How Is It Defined?

HSDD is a persistent or recurrent lack of sexual desire that causes personal distress. The desire is not simply low by cultural or partner comparison. It is low in a way that bothers you. That distress criterion is what separates a clinical diagnosis from a normal variation in libido.

The diagnostic language has evolved. The DSM-5 (2013) merged HSDD with Female Sexual Arousal Disorder into a single category called Female Sexual Interest/Arousal Disorder (FSIAD). Many clinicians, particularly those who work in sexual medicine, still use the term HSDD because the research literature, existing drug approvals, and patient language center on it. ISSWSH (the International Society for the Study of Women's Sexual Health) continues to use HSDD in its clinical practice statements and consensus documents.

The Distress Requirement

Guideline bodies are consistent on one point: desire deficit alone is not enough. ISSWSH's 2019 process-of-care consensus states explicitly that clinically significant personal distress or interpersonal difficulty must accompany the low desire for a diagnosis to apply. This matters because population surveys consistently show that a far larger percentage of women report low desire than the 10% who report distress related to it.

The DSDS Screener

The Decreased Sexual Desire Screener (DSDS) is a validated five-question tool developed specifically to identify generalized acquired HSDD in women. A 2010 validation study in the Journal of Sexual Medicine showed sensitivity of 85% and specificity of 88% in primary care settings. ACOG's 2019 committee opinion on female sexual dysfunction recommends using a validated screener as the first clinical step rather than relying on unstructured history alone.

How the Major Guidelines Compare on Diagnosis

No single organization has produced a single definitive HSDD-only diagnostic guideline in the way that, say, the ADA publishes diabetes standards. Instead, HSDD guidance is distributed across sexual medicine, gynecology, and endocrinology bodies. Here is where each stands.

ISSWSH

ISSWSH publishes the most detailed HSDD-specific clinical guidance of any society. Its 2021 process-of-care consensus for the identification and treatment of HSDD recommends a structured biopsychosocial assessment covering medical history, medications, relationship context, and mental health. The consensus explicitly names hormonal contributors including low androgen states, hormonal contraception effects, and menopause as factors to assess before diagnosing primary HSDD.

The Menopause Society (formerly NAMS)

The Menopause Society's 2022 position statement on hormone therapy addresses sexual function as one of the quality-of-life domains affected by menopause. It does not use HSDD as its primary framing but supports assessment and treatment of low desire in the context of the menopausal transition. The society endorses testosterone for postmenopausal women when other causes have been excluded, while acknowledging the absence of an FDA-approved formulation for women in the US.

ACOG

ACOG's Committee Opinion 659 on female sexual dysfunction (reaffirmed in 2020) frames HSDD as the most common female sexual dysfunction and recommends screening all women for sexual concerns as part of routine well-woman care. ACOG notes that clinicians should assess for contributing factors including depression, relationship distress, medications, and hormonal status before attributing symptoms to primary HSDD.

AACE and the Endocrine Society

Neither AACE nor the Endocrine Society has a standalone HSDD guideline. The Endocrine Society's 2019 guideline on androgen therapy in women is the most relevant document from endocrinology. It recommends against testosterone therapy for most indications in women except HSDD in postmenopausal women, where it endorses short-term use at physiologic premenopausal concentrations after shared decision-making. The guideline strongly discourages supraphysiologic dosing.

USPSTF

The US Preventive Services Task Force does not recommend routine screening for sexual dysfunction as a preventive service in asymptomatic women. This does not mean USPSTF opposes treatment; it simply has not found sufficient evidence to recommend population-level screening. If you raise sexual concerns with your clinician, that is a different situation from asymptomatic screening.

The table below summarizes the key diagnostic positions across guidelines.

| Society | Diagnostic Framework | Screener Endorsed | Hormonal Assessment Required | |---|---|---|---| | ISSWSH | HSDD (biopsychosocial model) | DSDS | Yes, explicitly | | The Menopause Society | Menopause-related sexual dysfunction | Not specified | Yes, within menopause context | | ACOG | Female sexual dysfunction (HSDD as most common subtype) | Validated screener recommended | Yes | | Endocrine Society | Androgen deficiency context | Not specified | Yes, serum androgens | | USPSTF | No screening recommendation | None | N/A |

Treatment Guidelines Compared

This is where guideline bodies diverge most meaningfully, and where life stage matters most for you.

FDA-Approved Options

Two drugs carry FDA approval for HSDD, both in premenopausal women only.

Flibanserin (Addyi): Approved in 2015 for generalized acquired HSDD in premenopausal women. It acts on serotonin receptors (5-HT1A agonist, 5-HT2A antagonist) in the central nervous system. The key trials, BEGONIA and SNOWDROP, showed that women taking 100 mg daily had approximately 0.5 to 1.0 additional satisfying sexual events per month compared with placebo. The absolute benefit is modest, but statistically significant and meaningful to women who respond. Alcohol is contraindicated with flibanserin due to severe hypotension risk, a warning the FDA added as a Risk Evaluation and Mitigation Strategy (REMS) requirement.

Bremelanotide (Vyleesi): Approved in 2019 as an on-demand subcutaneous injection for premenopausal women. It is a melanocortin receptor agonist taken 45 minutes before anticipated sexual activity. The RECONNECT trial showed statistically significant improvements in desire scores and reduction in distress compared with placebo, though nausea affected approximately 40% of participants.

Where ISSWSH Stands on These Drugs

ISSWSH's 2021 consensus endorses both flibanserin and bremelanotide as appropriate first-line pharmacologic options for premenopausal women with generalized acquired HSDD after non-pharmacologic and hormonal causes have been addressed. The consensus notes that neither drug should be the first step if an underlying contributor (thyroid dysfunction, a depressant medication, a relationship factor) has not been addressed.

Testosterone for Postmenopausal Women

No testosterone product is FDA-approved for HSDD in women in the US. This is a genuine regulatory gap. The Endocrine Society's 2019 androgen guideline and the global consensus statement on testosterone use in women published jointly by multiple societies including The Menopause Society and ISSWSH recommend off-label testosterone at doses that replicate physiologic premenopausal serum levels (free testosterone in the normal premenopausal range) for postmenopausal women with HSDD who have not responded to other measures.

A 2019 meta-analysis in The Lancet Diabetes and Endocrinology covering 36 randomized trials and more than 8,000 women found that testosterone significantly improved sexual function scores, desire, arousal, orgasm, and pleasure compared with placebo or comparator, with the largest effects seen in postmenopausal women. Acne and increased hair growth were the most common adverse effects; serious cardiovascular or breast outcomes did not differ significantly from placebo over trial durations of up to 24 months.

Non-Pharmacologic Treatments: Where All Guidelines Agree

Every major guideline agrees that psychotherapy, specifically sex therapy and cognitive behavioral approaches, has strong evidence for HSDD independent of pharmacologic treatment. ACOG, ISSWSH, and The Menopause Society all state that psychotherapy should be offered alongside or before medication in most cases. A 2020 Cochrane review of psychological interventions for sexual dysfunction in women found moderate-quality evidence supporting CBT-based sex therapy for desire and arousal concerns.

Pelvic floor physical therapy is relevant when HSDD co-occurs with pain (which frequently happens in perimenopause and postmenopause due to GSM). ISSWSH addresses this overlap explicitly.

Hormonal Contraception and HSDD

Hormonal contraception is a frequently overlooked contributor to HSDD in reproductive-age women. Combined oral contraceptives (COCs) increase sex hormone-binding globulin (SHBG), which binds free testosterone and may reduce androgenic drive. A 2006 study in the Journal of Sexual Medicine found that SHBG remained elevated in some women for up to six months after stopping COCs. Neither ISSWSH nor ACOG recommends discontinuing contraception without thorough counseling, but both flag this as an essential part of the HSDD history.

HSDD Across Life Stages

Your hormonal environment changes dramatically across your reproductive life, and HSDD does not present or respond to treatment the same way at every stage.

Reproductive Years (Ages 18 to ~42)

HSDD in this group is most commonly acquired and situational, though it can be generalized. Medication effects (antidepressants, hormonal contraception), relationship factors, postpartum hormonal changes, and mental health conditions are the most common contributors. Flibanserin and bremelanotide are both approved for this life stage. Psychotherapy has the strongest evidence base here.

Perimenopause (~42 to 52)

This is a high-risk period for HSDD onset. Estrogen fluctuation and eventual decline, combined with falling androgens, can produce a rapid reduction in desire. Genitourinary syndrome of menopause (GSM) frequently co-occurs, making penetrative sex painful and compounding desire loss. The Menopause Society recommends treating GSM first with local estrogen or ospemifene before attributing desire loss entirely to central HSDD pathways.

Flibanserin does not carry an FDA indication for perimenopausal women, a practical gap because many women in their late 40s are still having menstrual cycles. Clinicians must use clinical judgment here; some ISSWSH guidance supports off-label use in this transition period.

Postmenopause

Postmenopausal women have the highest prevalence of HSDD. Off-label testosterone, discussed above, has the strongest evidence base for this group. Estrogen therapy, where appropriate, addresses GSM and may indirectly improve desire by reducing pain and improving genital sensitivity. The Endocrine Society advises measuring total and free testosterone at baseline before initiating therapy and monitoring every six months during treatment.

Postpartum and Lactation

Low desire is extremely common postpartum. Prolactin suppresses GnRH, which reduces estrogen and testosterone. Breastfeeding compounds this. Most postpartum low desire resolves within six to twelve months after weaning. ISSWSH advises against diagnosing HSDD in the postpartum period until lactation has ceased and hormonal recovery has had time to occur. Neither flibanserin nor bremelanotide should be used while breastfeeding (see Pregnancy and Lactation section below).

Pregnancy and Lactation Safety

This section is mandatory reading if you are pregnant, trying to conceive, or breastfeeding.

Flibanserin

Flibanserin is classified as Pregnancy Category C based on animal data showing embryofetal effects at high doses. There are no adequate human pregnancy studies. Because HSDD is a non-life-threatening condition, flibanserin should be discontinued before conception attempts. Women using flibanserin must use effective contraception throughout treatment. Flibanserin is excreted in rat milk; human lactation data are absent, and because of this uncertainty the FDA label advises against use during breastfeeding.

Bremelanotide

Bremelanotide carries similar pregnancy concerns. Animal studies showed fetal weight reduction and skeletal abnormalities at doses above therapeutic range. The FDA label contraindicates use in pregnancy. Women of reproductive age must use reliable contraception. Lactation data are not available; bremelanotide should not be used while breastfeeding.

Testosterone (off-label, postmenopausal use)

Testosterone is a Category X teratogen in pregnancy due to the risk of virilization of a female fetus. Although postmenopausal women are not cycling, any woman who may still have any residual fertility (late perimenopause) must use contraception when using testosterone. The Endocrine Society guideline is explicit on this point.

Practical Guidance

If you are trying to conceive, discuss stopping any HSDD pharmacotherapy with your clinician at least one full menstrual cycle before discontinuing contraception. If you become pregnant while on any of these agents, stop immediately and contact your OB-GYN or MFM provider.

Who This Is Right for and Who Should Take a Different Approach

Candidates for pharmacologic HSDD treatment

• Premenopausal women with confirmed generalized acquired HSDD (distress present, other causes excluded), where psychotherapy alone has not been sufficient.
• Postmenopausal women with HSDD where GSM has been treated, relationship factors have been addressed, and testosterone has been discussed in shared decision-making.
• Women who have had a medication review ruling out SSRI-induced or contraceptive-induced desire loss as the primary driver.

Women for whom other steps come first

• Women whose low desire began with a specific life event or relationship problem. Psychotherapy is the first step.
• Women currently on SSRIs or SNRIs for depression. Bupropion switch or addition is worth discussing with your prescriber; desire suppression is a class effect of most SSRIs and should be addressed at source.
• Women with untreated thyroid disease. Hypothyroidism independently reduces libido; treating hypothyroidism often restores desire without additional intervention.
• Women in the first twelve months postpartum and currently breastfeeding. Watchful waiting with support is appropriate before any diagnostic label or pharmacotherapy.
• Women with active alcohol use disorder; flibanserin is contraindicated.

The Evidence Gap in Women

The HSDD trial literature has a documented representation problem. The BEGONIA and SNOWDROP flibanserin trials enrolled predominantly white women in the United States and Europe. The RECONNECT bremelanotide trials had similarly limited demographic diversity. A 2021 commentary in the Journal of Women's Health noted that Black, Latina, and Asian women remain underrepresented in sexual dysfunction trials despite evidence that cultural context, systemic stress, and partner dynamics may shape both desire and distress differently across groups.

Postmenopausal women are better represented in the testosterone literature, but many of those trials used older formulations at inconsistent doses, making cross-study comparison difficult. The absence of an FDA-approved testosterone product for women means that prescribers work without the standardized dosing data that a formal approval process would require.

Women have historically been told their sexual concerns are psychological. The growing guideline consensus across ISSWSH, ACOG, and The Menopause Society is pushing back on that assumption by treating HSDD as a medical condition with biological, psychological, and relational components, all of which deserve clinical attention.

Common Misconceptions About HSDD

"Low desire is just part of getting older." Age-related hormonal change is real, but it does not mean distressing desire loss is something you have to accept. Guideline bodies now consistently frame treatable HSDD as distinct from normal variation.

"If my partner wanted sex more often, I wouldn't have a problem." HSDD is diagnosed as generalized (present across all contexts and partners) or situational (context-dependent). If desire is absent in all sexual contexts including self-directed desire, the etiology is more likely biological or psychological rather than purely relational.

"Flibanserin is just 'pink Viagra'." This comparison is mechanistically wrong. Sildenafil works on vascular smooth muscle in the genitals. Flibanserin works centrally on serotonin and dopamine balance. The mode of action, the timing, and the patient population are completely different.

"My doctor can't help because there's no approved drug for postmenopausal HSDD." Off-label testosterone at physiologic doses is supported by multiple international society guidelines and a strong meta-analytic evidence base. Ask specifically about this option.